Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. More Details
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Lifespot Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LSH is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: LSH's weekly volatility has decreased from 28% to 14% over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
AU Healthcare Services
1 Year Return
AU Healthcare Services
Return vs Industry: LSH exceeded the Australian Healthcare Services industry which returned 15.1% over the past year.
Return vs Market: LSH exceeded the Australian Market which returned 0.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Lifespot Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StIf You Had Bought Lifespot Health (ASX:LSH) Stock Three Years Ago, You'd Be Sitting On A 78% Loss, Today
7 months ago | Simply Wall StCould The Lifespot Health Ltd (ASX:LSH) Ownership Structure Tell Us Something Useful?
9 months ago | Simply Wall StThe Lifespot Health (ASX:LSH) Share Price Is Down 89% So Some Shareholders Are Rather Upset
Is Lifespot Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LSH is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.
PE vs Market: LSH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LSH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LSH is overvalued based on its PB Ratio (17.9x) compared to the AU Healthcare Services industry average (5.5x).
How is Lifespot Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lifespot Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Lifespot Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Lifespot Health competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Lifespot Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LSH is currently unprofitable.
Growing Profit Margin: LSH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LSH is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.
Accelerating Growth: Unable to compare LSH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-6.6%).
Return on Equity
High ROE: LSH has a negative Return on Equity (-376.34%), as it is currently unprofitable.
How is Lifespot Health's financial position?
Financial Position Analysis
Short Term Liabilities: LSH's short term assets (A$656.6K) exceed its short term liabilities (A$232.6K).
Long Term Liabilities: LSH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LSH is debt free.
Reducing Debt: LSH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LSH has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LSH is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.
What is Lifespot Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LSH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LSH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LSH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Matthew Golden serves as Chief Executive Officer at Lifespot Health Ltd since October 12, 2020. Mr. Golden is a commercial healthcare Professional with experience in the pharmaceutical industry both in...
|Company Secretary & Non-Executive Director||0.58yr||AU$1.00k||no data|
|Non-Executive Director||4.67yrs||AU$58.06k||no data|
|Non-Executive Chairman||2.67yrs||AU$152.26k||0.35% |
Experienced Board: LSH's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LSH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.7%.
Lifespot Health Ltd's company bio, employee growth, exchange listings and data sources
- Name: Lifespot Health Ltd
- Ticker: LSH
- Exchange: ASX
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$11.995m
- Shares outstanding: 134.77m
- Website: https://www.lifespot-health.com
- Lifespot Health Ltd
- 2 Queen Street
- Suite 103
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LSH||ASX (Australian Securities Exchange)||Yes||Common stock||AU||AUD||Jan 2017|
|LSH||CHIA (Chi-X Australia)||Yes||Common stock||AU||AUD||Jan 2017|
|L2H||DB (Deutsche Boerse AG)||Yes||Common stock||DE||EUR||Jan 2017|
Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. The company is deve...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/05 07:08|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.